Advice
Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall
Eli Lilly, Zepbound, obesity drug, Q4 2024 earnings, pharmaceutical revenue, GLP-1 medications, Mounjaro, 2025 guidance
Pfizer Exceeds Q4 Expectations: COVID-19 Products and Cost-Cutting Drive Strong Performance
Pfizer, Q4 earnings, COVID-19 portfolio, cost-cutting initiatives, revenue growth, Paxlovid, financial recovery, 2025 guidance
FDA Introduces New Guidance on AI for Drug Approval Submissions in 2025
FDA, AI, drug approval, guidance, regulatory decision-making, medical devices, artificial intelligence, drug development
Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook
Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention
Bristol Myers Squibb Posts Strong Q3 Results, Boosts 2024 Guidance on Robust Sales of Legacy and New Drugs
Bristol Myers Squibb, Q3 earnings, 2024 guidance, legacy drugs, newer drugs, pharmaceutical industry, financial performance
Merck Reports Strong Q3 Results but Lowers Full-Year Sales Guidance
Merck, Q3 Results, Full-Year Sales Guidance, Keytruda, Gardasil, Januvia, Winrevair, Capvaxive
AI Guidance for Investors: Navigating the Future with Strategic Approaches and Regulatory Insights
AI Guidance for Investors, Strategic AI Adoption, Regulatory Impact on AI, Cybersecurity Risks in AI, AI Mapping Strategies, Data Governance in AI, Future of AI in Healthcare
FDA Updates Guidance to Combat Online Misinformation About Medical Products
FDA, online misinformation, medical products, guidance, regulatory clarity, public health
Dexcom Stock Plummets 40% After Disappointing CGM Sales and Weak Guidance
Dexcom, CGM, Sales Challenges, Stock Drop, Weak Guidance
Johnson & Johnson Raises 2024 Guidance Following Acquisition of Shockwave Medical
Johnson & Johnson, Shockwave Medical, 2024 Guidance, Acquisition, Billion-Dollar Potential